Thrombocytopenia Evaluation and Management in ICU Patients

Introduction to Thrombocytopenia

The American Society of Hematology recommends immediate assessment of platelet count severity and bleeding risk in ICU patients with thrombocytopenia, using the 4T score for heparin-induced thrombocytopenia (HIT) and targeted diagnostic workup based on clinical context 1, 2

Assess bleeding symptoms immediately, looking for petechiae, purpura, mucosal bleeding, hemoptysis, hematuria, gastrointestinal bleeding, or intracranial hemorrhage in patients with thrombocytopenia 3, 4

Days 0-3 post-admission/surgery: Hemodilution from resuscitation, consumption from massive transfusion, or perioperative platelet consumption in extracorporeal circuits are common causes of thrombocytopenia 1, 2
Days 5-10: HIT is the primary concern, and the 4T score should be calculated immediately 1, 2

The 4T score is mandatory for any ICU patient with thrombocytopenia and heparin exposure, with a score of 0-3 points indicating low probability of HIT, 4-5 points indicating intermediate probability, and 6-8 points indicating high probability 1, 2

If thrombocytopenia and thrombosis are present, consider antiphospholipid syndrome, thrombotic thrombocytopenic purpura (TTP), or disseminated intravascular coagulation (DIC) 1, 2, 3
If isolated thrombocytopenia without thrombosis is present, consider sepsis, drug-induced thrombocytopenia, liver disease with portal hypertension, post-transfusion purpura, or chemotherapy/bone marrow suppression 1, 2, 5

Order a complete blood count with differential and blood smear review, PT/INR, aPTT, fibrinogen, D-dimer, and peripheral blood smear in patients with thrombocytopenia 3

For platelets ≥50 × 10⁹/L, no platelet transfusion is needed unless active major bleeding is present, and full-dose anticoagulation is safe if indicated for thrombosis 7, 5, 6
For platelets 25-50 × 10⁹/L, reduce LMWH to 50% therapeutic dose or prophylactic dosing for cancer-associated thrombosis with lower thrombotic risk, and target platelet count >50 × 10⁹/L for general bleeding 7, 5, 8
For platelets <25 × 10⁹/L, temporarily discontinue anticoagulation unless life-threatening thrombosis, and consider prophylactic platelet transfusion if platelets <10 × 10⁹/L to prevent spontaneous bleeding 8, 3

Transfuse to achieve minimum platelet counts before procedures, such as central venous catheter insertion (20 × 10⁹/L), lumbar puncture (40 × 10⁹/L), major surgery or percutaneous tracheostomy (50 × 10⁹/L), percutaneous liver biopsy (50 × 10⁹/L), epidural catheter insertion/removal (80 × 10⁹/L), and neurosurgery or posterior segment eye surgery (100 × 10⁹/L) 6, 3, 8

If HIT is confirmed, stop all heparin immediately, start alternative anticoagulation at therapeutic dose, and screen for thrombosis with bilateral lower extremity Doppler ultrasound 1, 2
If immune thrombocytopenia (ITP) is suspected, treat with prednisone, IVIg, or romiplostim, and target platelet count ≥50 × 10⁹/L to reduce bleeding risk 8, 3
If sepsis-related thrombocytopenia is present, treat the underlying infection, and consider prophylactic transfusion threshold of 10 × 10⁹/L 6
If DIC is present, treat the underlying cause, transfuse platelets if <50 × 10⁹/L with active bleeding, and consider cryoprecipitate if fibrinogen <100 mg/dL 1, 6

Monitor daily platelet counts when <50 × 10⁹/L with active bleeding or requiring anticoagulation, weekly during dose adjustment phase of any treatment, and monthly after establishing stable treatment dose 3
Monitor for at least 2 weeks after discontinuing heparin or thrombopoietin receptor agonists 2